BidaskClub cut shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a sell rating to a strong sell rating in a research report released on Saturday, August 5th.
Other analysts have also recently issued reports about the company. Maxim Group lowered their target price on Achillion Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a research report on Tuesday, April 25th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, July 18th. Jefferies Group LLC restated a hold rating on shares of Achillion Pharmaceuticals in a research report on Wednesday, April 26th. Robert W. Baird raised their target price on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an outperform rating in a research report on Monday, April 24th. Finally, Leerink Swann upgraded Achillion Pharmaceuticals from a market perform rating to an outperform rating and raised their target price for the company from $4.00 to $6.00 in a research report on Thursday, May 18th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $8.25.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded down 4.30% on Friday, reaching $4.67. The company had a trading volume of 1,489,155 shares. The stock has a 50 day moving average price of $4.45 and a 200-day moving average price of $4.16. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.49. The company’s market capitalization is $638.67 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). During the same period last year, the firm earned ($0.14) earnings per share. Analysts forecast that Achillion Pharmaceuticals will post ($0.63) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Rincon Hill News and is the property of of Rincon Hill News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://rinconhillneighbors.org/2017/08/19/achillion-pharmaceuticals-inc-nasdaqachn-cut-to-strong-sell-at-bidaskclub-updated.html.
Several institutional investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. raised its position in Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 800 shares during the last quarter. Deschutes Portfolio Strategy LLC raised its position in shares of Achillion Pharmaceuticals by 13.4% in the first quarter. Deschutes Portfolio Strategy LLC now owns 25,430 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 3,000 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares in the last quarter. Teza Capital Management LLC purchased a new position in shares of Achillion Pharmaceuticals during the first quarter valued at about $131,000. Finally, TradeLink Capital LLC purchased a new position in shares of Achillion Pharmaceuticals during the second quarter valued at about $132,000. Institutional investors and hedge funds own 70.70% of the company’s stock.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.